权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular models to characterize actions of calcium sensitizing drugs

表征钙增敏药物作用的分子模型

基本信息

批准号：
10307610
负责人：
Steffen Lindert
金额：
$ 36.29万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-01-15 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10307610
关键词：
Address Adrenergic Agents Adrenergic beta-Agonists Affinity Binding Calcium Calcium Binding Cardiac Cardiac Myocytes Collaborations Computer Assisted Computer Models Computing Methodologies Data Development Drug Design Drug Sensitization Drug Targeting Drug usage Dyes Feedback Fluorescence Fluorescence Spectroscopy Free Energy Functional disorder Heart Heart Diseases Heart failure Hematological Disease High Performance Computing Hydrophobicity Interdisciplinary Study Intervention Kinetics Knowledge Left Link Lung diseases Measurement Methodology Methods Microfilaments Mission Modeling Molecular Molecular Conformation Myocardial Contraction Ohio Pathway interactions Patients Peptides Pharmaceutical Preparations Pharmacologic Substance Predictive Value Prevention Procedures Process Proteins Public Health Relaxation Research Research Design Resolution Societies Structure Testing Thermodynamics Thin Filament Troponin United States National Institutes of Health Ventricular Work base blind drug candidate drug discovery experience experimental study human disease improved inhibitor method development molecular dynamics molecular modeling mutant novel novel strategies phosphoric diester hydrolase programs screening side effect simulation supercomputer tool

项目摘要

Project Summary / Abstract Heart failure is a pressing problem in today’s society. Positive inotropic agents are needed in the treatment of heart failure due to left ventricular systolic dysfunction. Many of the currently used drugs (such as β-adrenergic agonists and phosphodiesterase III inhibitors) are ineffective in the long-term since they are plagued with severe side effects. Calcium sensitizing agents are interesting alternative drug candidates if they can cause a positive inotropic effect without associated side effects. One possible target for calcium sensitizing drugs is cardiac troponin (cTn), a Ca2+-dependent switch, activating and deactivating the myofilament leading to contraction and relaxation. Cardiac cTn consists of three subunits: cTnC, cTnI and cTnT. Increasingly routine computational methods are used to study cTn. However, there remains a critical need for development of novel and more precise tools that expand understanding of molecular processes governing heart contraction in order to guide targeted drug discovery studies. The main objective of this proposal is to develop novel computational methods to predict and modulate calcium sensitization within cTnC. Results from computational method advances will be verified experimentally and the experimental results will drive additional method refinement. The proposed research is structured into three main stages. We will use computer-aided drug design studies to find and experimentally verify novel calcium sensitizing agents (Aim I) and then develop computational models to understand the molecular processes in cTn that underlie the observed sensitizing effect with direct feedback to experiments (Aims II and III). Method development work will focus on overcoming two main hurdles faced by current computational models of cardiomyocyte contraction. Firstly, we will develop new methodology to accurately predict calcium binding affinities to cTnC (Aim II). Based on strong preliminary data, we hypothesize that this requires polarizable force fields, without which Ca2+ binding is not adequately modeled and oversimplified in molecular dynamics (MD) simulations. Secondly, we will predict the degree to which drugs open up the cTnC-cTnI interface (Aim III). Based on preliminary data, our hypothesis is that microsecond MD simulations and new methodology are needed to determine the opening degree of the hydrophobic patch in drug-bound conformations. Results from computational method advances will be verified experimentally and the experimental results will drive additional method refinement and improve our initial drug discovery hits.

项目概要/摘要心力衰竭是当今社会的一个紧迫问题。需要正性肌力药物治疗左心室收缩功能障碍所致的心力衰竭。目前使用的许多药物（如β-肾上腺素能激动剂和磷酸二酯酶III抑制剂）长期无效因为它们受到严重副作用的困扰。钙敏化剂是有趣的替代品候选药物是否可以引起正性肌力作用而不产生相关副作用。一钙增敏药物的可能目标是心肌肌钙蛋白 (cTn)，一种 Ca2+ 依赖性开关，激活和停用肌丝，导致收缩和放松。心脏肌钙蛋白由三个亚基组成：cTnC、cTnI 和 cTnT。越来越常规的计算方法是用于研究 cTn。然而，仍然迫切需要开发新颖且更精确的扩大对控制心脏收缩的分子过程的理解的工具，以指导靶向药物发现研究。该提案的主要目标是开发新颖的预测和调节 cTnC 内钙敏化的计算方法。结果计算方法的进步将得到实验验证，并且实验结果将推动进一步的方法改进。拟议的研究分为三个部分主要阶段。我们将使用计算机辅助药物设计研究来寻找并通过实验验证新颖的药物钙敏化剂（目标 I），然后开发计算模型来了解 cTn 中的分子过程是观察到的敏化效应的基础，并直接反馈到实验（目标 II 和 III）。方法开发工作将侧重于克服两个主要障碍面临当前心肌细胞收缩的计算模型。首先，我们将开发新的准确预测钙与 cTnC 结合亲和力的方法（目标 II）。立足于强初步数据，我们假设这需要极化力场，没有Ca2+ 在分子动力学（MD）模拟中，结合没有得到充分的建模和过度简化。其次，我们将预测药物打开 cTnC-cTnI 界面的程度（目标 III）。基于根据初步数据，我们的假设是微秒MD模拟和新方法是需要确定药物结合构象中疏水补片的开放程度。计算方法进步的结果将通过实验进行验证，并且实验结果将推动进一步的方法改进并提高我们最初的药物发现命中率。